sb 211475 has been researched along with mocetinostat in 3 studies
| Studies (sb 211475) | Trials (sb 211475) | Recent Studies (post-2010) (sb 211475) | Studies (mocetinostat) | Trials (mocetinostat) | Recent Studies (post-2010) (mocetinostat) |
|---|---|---|---|---|---|
| 6 | 0 | 1 | 21,735 | 390 | 8,606 |
| Protein | Taxonomy | sb 211475 (IC50) | mocetinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.7851 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.022 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.57 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.102 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.102 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.3433 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3537 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.6386 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.6725 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christopher, TA; Feuerstein, GZ; Lopez, BL; Ma, XL; Ruffolo, RR; Yue, TL | 1 |
| Brunvand, H; Feuerstein, GZ; Liu, G; Ma, XL; Ruffolo, RR; Yue, TL | 1 |
| Chen, J; Christopher, TA; Gao, F; Gu, J; Lopez, BL; Lysko, P; Ma, XL; Ohlstein, EH; Ruffolo, RR; Yue, TL | 1 |
3 other study(ies) available for sb 211475 and mocetinostat
| Article | Year |
|---|---|
Effects of a hydroxylated metabolite of the beta-andrenoreceptor antagonist, carvedilol, on post-ischaemic splachnic tissue injury.
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Blood Pressure; Carbazoles; Carvedilol; Endothelium, Vascular; In Vitro Techniques; Ischemia; Male; Mesenteric Artery, Superior; Muscle Relaxation; Muscle, Smooth, Vascular; Peroxidase; Propanolamines; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 1998 |
SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Hemodynamics; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Peroxidase; Propanolamines; Rabbits | 1998 |
Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Bisoprolol; Carbazoles; Cardiovascular Agents; Carvedilol; Creatine Kinase; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Rate; Isoproterenol; Lipid Peroxidation; Male; Membrane Lipids; Myocardial Ischemia; Myocardium; Peroxidase; Propanolamines; Rabbits; Reperfusion Injury; Ventricular Pressure | 2000 |